Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric isavuconazonium sulfate study in invasive aspergillosis or invasive mucormycosis
2018-003975-36Phase 2Unknown
- Sponsor
- Astellas Pharma
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isavuconazonium in invasive aspergillosis (IA) and mucormycosis, sponsored by Astellas Pharma. Primary endpoint: Safety outcomes. Status: unknown.
02
Drugs
isavuconazonium
03
Conditions
invasive aspergillosis (IA)mucormycosis
Beyond the preview
Go deeper on 2018-003975-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003975-36.